Mission Bio s Tapestri Platform Helps Understand Cancer Therapy Resistance in New Solid Tumor Study prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Mission Bio, the life sciences company delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market for new therapeutics, announced today a new peer-reviewed study published using the Tapestri Platform's single-cell multi-omics solution to accurately distinguish leukemic cells from clonal hematopoiesis of indeterminate potential (CHIP) in relapsed AML patients. These findings highlight the potential of single-cell proteogenomics to vastly improve disease monitoring post-treatment, specifically for measurable residual disease (MRD) in hematological malignancies. The study was led by Christopher S. Hourigan, MD, DPhil, Chief of Myeloid Malignancies at the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, and published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.
Mission Bio Launches Pharma Assay Development Services to Speed Access to New Technologies
New service reduces project time from months to weeks for biopharma customers
News provided by
Share this article
SOUTH SAN FRANCISCO, Calif., April 20, 2021 /PRNewswire/
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced the launch of its Pharma Assay Development (PAD) services to accelerate biomarker discovery and cell and gene therapy development pipelines for biopharma customers. The PAD Team will provide customers with early access to services based on the latest new technological innovations, in addition to services on Mission Bio s existing products to implement Single Cell Multiomics capabilities into discovery, translational and clinical research efforts. Mission Bio has appointed Harsha Kavuri to head up the PAD Team as General Manager, affirming its strategic focus to service the dynamic needs of customers working in areas
Global Single Cell Genomics Market Report 2021-2025: Single Cell Genomics Identifying New Forms of Life, Driving Enormous New Research Area with Wide Health Care Applications prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Tyler Jacks, Ph.D., after 19 years. The director role will be taken over by
Matthew Vander Heiden, M.D., Ph.D., a professor of biology at MIT and a medical oncologist at Dana-Farber Cancer Institute. He became a member of the Koch Institute in 2010 and took over for Jacks on Thursday, MIT said. Jacks will continue to lead the Bridge Project, which unites bioegnineers, cancer scientists and clinical oncologists from the Koch Institute and the Dana-Farber/Harvard Cancer Center.
> Atara Biotherapeutics ushered
Amie Krause into the role of senior vice president and chief people officer April 2. Since joining the company, Krause has been the driving force behind Atara’s human people department, advocating for employees across the organization. She doubles as a founding leader of Atara’s Women’s Alliance and is part of the Healthcare Businesswomen’s Association. Before signing on with Atara, Krause held several top human resources roles at Amgen, including HR lead for the